

## SUPPLEMENTARY PROSPECTUS

### MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED ACN 106 340 667

#### 1. Important information

This document is a supplementary prospectus (**Supplementary Prospectus**) which supplements and should be read together with Medical Developments International Limited ACN 106 340 667 (**MVP**) prospectus dated 4 August 2022 (**Prospectus**).

Under section 719(4) of the *Corporations Act 2001* (Cth) (**Corporations Act**), the information set out below together with the Prospectus is taken to be the Prospectus for the purposes of the application of Chapter 6D of the Corporations Act to events that occur after the lodgement of this Supplementary Prospectus with ASIC.

Terms defined in the Prospectus have the same meaning in this Supplementary Prospectus, unless stated otherwise.

This Supplementary Prospectus is dated and was lodged with ASIC on 25 August 2022. None of ASIC, the ASX and their respective officers take responsibility for the contents of this Supplementary Prospectus.

Other than set out below, all details in the Prospectus remain unchanged. To the extent that there are any inconsistencies between this Supplementary Prospectus and the Prospectus, this Supplementary Prospectus will prevail.

#### 2. Description of Entitlement Offer on cover page

In relation to the description of the Entitlement Offer on the cover page of the Prospectus, MVP confirms that the Retail Entitlement Offer which is being made under the Prospectus involves an offer of approximately 5.0 million New Shares at the Offer Price of \$2.00 per New Share which is expected to raise approximately \$10.0 million. The Entitlement Offer, which includes both the Retail Entitlement Offer and Institutional Entitlement Offer, is expected to raise approximately \$15.0 million in total.

#### 3. Proposed use of funds

Further to the disclosure in Section 4.1, more detailed disclosure as to the proposed use of funds raised from the Entitlement Offer and Placement is set out below.

Purpose	Entitlement Offer and Placement (\$ million)
Investment in in-region/in-market resources that will support the growth in Australia and Europe respectively, along with enhanced organisational capability (i.e. further specialised employees)	15.3
Clinical trials and research and development	5.5
New product development	2.7
Manufacturing improvements	3.0
Working Capital	2.0

Capital Raising Costs	1.5
<b>Total funds raised</b>	<b>30.0</b>

#### 4. Effect of the Capital Raising on control of the Company

Further to the disclosure in Section 4.6, MVP notes that if Mr David Williams takes up his Entitlement and sub-underwrites the Retail Entitlement Offer to the full amount of his sub-underwriting commitment of \$500,000, Mr Williams' shareholding in the Company will reduce from 13.35% to approximately 12.5% as he did not participate in the Placement.

#### 5. Related party arrangements


Section 6.8(d) (Related party arrangements) is replaced with the following:

*'The only related party arrangements are the Directors' sub-underwriting arrangements as set out in Section 6.8(b). These arrangements are considered to be on arm's length terms as they are materially in the same form as the arrangements with the other sub-underwriters, who are independent institutional, sophisticated and professional investors.'*

#### 6. DIRECTORS' AUTHORISATION

This Supplementary Prospectus is issued by the Company and its issue has been authorised by each Director of the Company.

In accordance with section 720 of the Corporations Act, each Director has given and has not withdrawn their consent to the lodgement of this Supplementary Prospectus with ASIC.



.....  
Tara Eaton  
Company Secretary  
**Medical Developments International Limited**